Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer - Patel, Jyoti D.; Hensing, Thomas A.; Rademaker, Alfred; Hart, Eric M.; Blum, Matthew G.; Milton, Daniel T.; Bonomi, Philip D. (Journal of clinical oncology, 2009)
Keywords: Adult; Aged; Aged, 80 and over; Anemia - chemically induced; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab; Biological and medical sciences; Carboplatin - administration & dosage; Carboplatin - adverse effects; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Disease-Free Survival; Drug Administration Schedule; Fatigue - chemically induced; Female; Follow-Up Studies; Glutamates - administration & dosage; Glutamates - adverse effects; Guanine - administration & dosage; Guanine - adverse effects; Guanine - analogs & derivatives; Humans; Kaplan-Meier Estimate; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Medical sciences; Middle Aged; Neoplasm Staging; Neutropenia - chemically induced; Pemetrexed; Pneumology; Thrombocytopenia - chemically induced; Treatment Outcome; Tumors; Tumors of the respiratory system and mediastinum; Antineoplastic agent; Lung disease; Respiratory disease; Lung cancer; Monoclonal antibody; Malignant tumor; non-small cell lung carcinoma; Pemetrexed; Bevacizumab; First line treatment; Antifolate; Cancerology; Vascular endothelium growth factor; Phase II trial; Carboplatin; Bronchus disease; Antiangiogenic agent; Cancer; Platinum II Complexes